ImmunityBio's ANKTIVA Combination Therapy Achieves Primary Goal in Bladder Cancer Study

ImmunityBio, Inc. reported positive final results from its Phase 3 QUILT-2.005 trial, where the ANKTIVA and BCG combination met its primary endpoint for high-grade non-muscle invasive bladder cancer. This chemotherapy-free treatment showed significantly improved efficacy over BCG alone in BCG-naïve patients. The findings could offer a new therapeutic option for bladder cancer, with further details expected at a medical congress.